肿瘤浸润性CD8+淋巴细胞可预测乳腺癌的临床结局

Tumor-Infiltrating CD8 Lymphocytes Predict Clinical Outcome in Breast Cancer
作者:"Sahar M.A. Mahmoud, Emma Claire Paish, Desmond G. 【View at publisher】 【全球专家评论】
期刊: J Clin Oncol2012年1月期卷 专家评级:★★ 循证评级:B

Breast carcinomas are often infiltrated by inflammatory cells, particularly macrophages and T lymphocytes, but the significance of these cells remains unclear. One possible role of these inflammatory cells is that they represent a cell-mediated immune response against the carcinoma. CD8+ lymphocytes are a known crucial component of cell-mediated immunity. The purpose of this study was to explore the prognostic value of tumor-infiltrating CD8+ cytotoxic lymphocytes in breast cancer. Tumor-infiltrating CD8+ lymphocytes were assessed by immunohistochemical staining of tissue microarray cores from 1,334 unselected breast tumors from patients with long-term follow-up. The number of CD8+ T cells was counted in tumor nests (intratumoral), in stroma adjacent to tumor cells, and in stroma distant to tumor cells, and their relationship with clinical outcome was determined. The total number of CD8+ cells was positively correlated with tumor grade (rs=0.20; P<.001) and inversely correlated with patient's age at diagnosis, estrogen receptor–alpha (ER-α), and progesterone receptor (PgR) expression (Mann-Whitney U test, P<.001). The total patient cohort was randomly divided into two separate training and validation sets before performing univariate survival analysis. Total number and distant stromal CD8+ lymphocytes were associated with better patient survival (P=.041 and P<.001, respectively) in the training set. In multivariate analysis, total CD8+ T-cell count was an independent prognostic factor in both training and validation sets. These results suggest that tumor-infiltrating CD8+ T lymphocytes have antitumor activity as judged by their favorable effect on patients' survival and could potentially be exploited in the treatment of breast cancer.

学科代码:肿瘤学   关键词:肿瘤浸润性CD8+淋巴细胞可预测乳腺癌的临床结局
来源: Eclips
Eclips介绍:Eclips由权威专家阅读世界顶级医学期刊(包括New England Journal of Medicine, The Lancet, JAMA, BMJ 等)后筛选出最顶尖的文章,并总结、分级和点评,为繁忙的临床医生提供最快、最有效的前沿医学信息,并同时提供临床医生参与点评文献和同行互动交流的学术平台。 请点击申请试用并填写联系信息,我们将每月为前100位申请者发送带有用户名、密码及网页链接的电子邮件,请您注意查收!感谢您的参与及使用! 马上访问Eclips网站http://eclips.consult.com/
顶一下(1
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录